Gorka Fius

Gorka brings extensive experience in various industries, such as aerospace and automotive, to his role as General Manager and Founder of Dreavent. His leadership style prioritizes productivity and excellence in customer service.

As CEO of a venture capital firm, Gorka has demonstrated proven proficiency in biotechnology investments. Under his leadership, Dreavent has established itself as a leading US biotechnology investment firm, with nearly $50 million invested in leading US biotech therapeutics companies.

Gorka meticulously built a high-caliber team, which includes experienced professionals who come from notable organizations such as Pfizer, Lilly, Abbvie Ventures or the Boston Biotech Forum. His strategic approach has achieved partnerships with major biotechnology investment players, facilitating investors' access to exclusive opportunities.

These partnerships involve co-investments with renowned pharmaceutical companies such as Novo Nordisk, Eli Lilly, Merck and Sanofi, as well as esteemed biotech funds such as 5AM, K2 and Abingworth. Gorka's dedication to driving innovation and fostering growth within the biotechnology industry continues to drive Dreavent's success.